Hans Clevers retiring as head of Roche’s pRED

After more than three years as head of Roche Pharma Resesarch and Early Development (pRED), Hans Clevers intends to retire from Roche (SIX:ROG; OTCQX:RHHBY) at the end of August. The pharma said it will name a successor in due course.

Clevers intends to remain in his position leading Roche’s Institute of Human Biology until a successor is found...